Artykuły w czasopismach na temat „BRCA2”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „BRCA2”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Friedlander, Michael, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Alla Sergeevna Lisyanskaya i in. "Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 5551. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5551.
Pełny tekst źródłaZhang, Yinuo. "BRCA1, BRCA2 and primary ovarian insufficiency". E3S Web of Conferences 165 (2020): 05009. http://dx.doi.org/10.1051/e3sconf/202016505009.
Pełny tekst źródłaWang, Aifen, Robert W. Holloway, Lijuan Cui, Yan Sun i Zihan Zhao. "Association betweenBRCA1 and BRCA2 mutations and prognosis in women with endometrial carcinoma." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e17115-e17115. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17115.
Pełny tekst źródłaPonce, Jordi, Sergi Fernandez-Gonzalez, Iris Calvo, Maite Climent, Judith Peñafiel, Lidia Feliubadaló, Alex Teulé i in. "Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers". International Journal of Gynecologic Cancer 30, nr 1 (27.11.2019): 83–88. http://dx.doi.org/10.1136/ijgc-2019-000626.
Pełny tekst źródłaLabidi-Galy, Sana Intidhar, Manuel Rodrigues, Jose L. Sandoval, Jean Emmanuel Kurtz, Florian Heitz, Anna Maria Mosconi, Ignacio Romero i in. "Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 5571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5571.
Pełny tekst źródłaLabidi-Galy, Sana Intidhar, Manuel Rodrigues, Jose L. Sandoval, Jean Emmanuel Kurtz, Florian Heitz, Anna Maria Mosconi, Ignacio Romero i in. "Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 5571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5571.
Pełny tekst źródłaRichters, Lisa Katharina, Philip C. Schouten, Stefan Kommoss, Jan Hauke, Alexander Burges, Dimo Dietrich, Ahmed El-Balat i in. "BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 5546. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5546.
Pełny tekst źródłaArun, Banu, Angelica Gutierrez Barrera, Rachel M. Layman, Stephen K. Gruschkus, Isabelle Bedrosian, Constance T. Albarracin, Carlos Hernando Barcenas, Vicente Valero, Jennifer Keating Litton i Debu Tripathy. "Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 1544. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1544.
Pełny tekst źródłaSy, Shirley M. H., Michael S. Y. Huen i Junjie Chen. "PALB2 is an integral component of the BRCA complex required for homologous recombination repair". Proceedings of the National Academy of Sciences 106, nr 17 (15.04.2009): 7155–60. http://dx.doi.org/10.1073/pnas.0811159106.
Pełny tekst źródłaShatavi, Seerin Viviane, Lindsay Dohany, Mohammad Muhsin Chisti, Ishmael A. Jaiyesimi i Dana Zakalik. "Unique genetic characteristics of BRCA mutation carriers in a cohort of Arab American women." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 1541. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1541.
Pełny tekst źródłaKeung, Yi-Kong, Adriana Hu, Annie Yeung, Amy Chan i Eddie Hu. "Higher prevalence of BRCA2 mutations among Chinese breast cancer patients in a community oncology clinic." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e12017-e12017. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e12017.
Pełny tekst źródłaKauff, Noah D., Susan M. Domchek, Tara M. Friebel, Mark E. Robson, Johanna Lee, Judy E. Garber, Claudine Isaacs i in. "Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study". Journal of Clinical Oncology 26, nr 8 (10.03.2008): 1331–37. http://dx.doi.org/10.1200/jco.2007.13.9626.
Pełny tekst źródłaPanda, Anshuman, Mark N. Stein, Gregory Riedlinger, Gyan Bhanot i Shridar Ganesan. "Role for immune checkpoint blockade in BRCA2-mutant prostate cancer." Journal of Clinical Oncology 37, nr 8_suppl (10.03.2019): 59. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.59.
Pełny tekst źródłaBracci, Ciarapica, Zabaleta, Tartaglione, Pirozzi, Giuliani, Piva i in. "BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work". Cancers 11, nr 8 (9.08.2019): 1146. http://dx.doi.org/10.3390/cancers11081146.
Pełny tekst źródłaChahla, Elie, Antonio Cheesman, Suzanne M. Mahon, Robert W. Garrett, Ben P. Bradenham, Theresa L. Schwartz, Louay Omran, Jason R. Taylor i Samer Alkaade. "Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations". Scientifica 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/5619358.
Pełny tekst źródłaFerrone, Cristina R., Douglas A. Levine, Laura H. Tang, Peter J. Allen, William Jarnagin, Murray F. Brennan, Kenneth Offit i Mark E. Robson. "BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma". Journal of Clinical Oncology 27, nr 3 (20.01.2009): 433–38. http://dx.doi.org/10.1200/jco.2008.18.5546.
Pełny tekst źródłaReisinger, Raquel, Sergiusz Wesolowski, Umang Swami, Pedro C. Barata, Edgar Javier Hernandez, Roberto Nussenzveig, Gordon Lemmon i in. "Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA)." Journal of Clinical Oncology 39, nr 6_suppl (20.02.2021): 162. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.162.
Pełny tekst źródłaFaermann, Renata, Eitan Friedman, Orit Kaidar-Person, Jonathan Weidenfeld, Malka Brodsky, Anat Shalmon, Osnat Halshtok Neiman i in. "Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers". Breast Journal 2022 (27.10.2022): 1–7. http://dx.doi.org/10.1155/2022/4317693.
Pełny tekst źródłaFoglietta, Jennifer, Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Maria Sole Reda, Antonella Al-Refaie, Francesca Romana Tofanetti i in. "Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study". Genes 11, nr 8 (12.08.2020): 925. http://dx.doi.org/10.3390/genes11080925.
Pełny tekst źródłaBisgin, Atil, Ibrahim Boga, Ozge Sonmezler, Cem Mujde, Abdullah Hanta i Sevcan Tug Bozdogan. "Meta-analysis and single-center experience on the comprehensive genomic characterization and landscape of BRCA1 and BRCA2 in Turkey." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e13611-e13611. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13611.
Pełny tekst źródłaKiechle, M. "Hereditäres Mammakarzinom: BRCA1, BRCA2 und BRCA3". Senologie - Zeitschrift für Mammadiagnostik und -therapie 8, nr 02 (czerwiec 2011): 103. http://dx.doi.org/10.1055/s-0031-1271518.
Pełny tekst źródłaKwong, A., L. Wong, C. Wong, F. Law, E. Tang, W. Chan, E. S. Ma, J. M. Ford i D. W. West. "Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): e22226-e22226. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e22226.
Pełny tekst źródłaZajchowski, Deborah A., Hugh Salamon i Ken D. Yamaguchi. "Proliferation pathway aberration frequencies in BRCA1- and BRCA2-mutated ovarian cancers." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 5074. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5074.
Pełny tekst źródłaLi, Jiaheng, Bojin Zhao, Teng Huang, Zixin Qin i San Ming Wang. "Human BRCA pathogenic variants were originated during recent human history". Life Science Alliance 5, nr 5 (14.02.2022): e202101263. http://dx.doi.org/10.26508/lsa.202101263.
Pełny tekst źródłaTun, N. M., G. M. Villani i K. Ong. "Risk of having BRCA mutations in women with triple-negative breast cancer: A systematic review and meta-analysis." Journal of Clinical Oncology 29, nr 27_suppl (20.09.2011): 160. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.160.
Pełny tekst źródłaNovikova, EI, EA Kudinova, VK Bozhenko i VA Solodkiy. "Characteristics of BRCA-associated breast cancer in the population of the Russian Federation". Features of HIV and SARS-CoV-2 coinfection in a pandemic, nr 2021(1) (luty 2021): 24–29. http://dx.doi.org/10.24075/brsmu.2021.006.
Pełny tekst źródłaWen, Lu, Xiuxiu Li, Junping Shi, Shuo Zhang, Rui Wang, Ming Yao i Jun Guo. "Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer". Journal of International Medical Research 48, nr 3 (27.11.2019): 030006051988622. http://dx.doi.org/10.1177/0300060519886226.
Pełny tekst źródłaRhiem, K., C. Fischer, K. Bosse, B. Wappenschmidt i R. K. Schmutzler. "Increased risk of cervical cancer in high-risk families with and without mutations in the BRCA1 and BRCA2 genes". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 5588. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5588.
Pełny tekst źródłaMcNevin, Ciara S., Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott i Stephen Finn. "Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer". Cancers 13, nr 22 (14.11.2021): 5697. http://dx.doi.org/10.3390/cancers13225697.
Pełny tekst źródłaChoi, Doo Ho, Min Hyuk Lee, Allen E. Bale, Darryl Carter i Bruce G. Haffty. "Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients". Journal of Clinical Oncology 22, nr 9 (1.05.2004): 1638–45. http://dx.doi.org/10.1200/jco.2004.04.179.
Pełny tekst źródłaCastro, Elena, David Olmos, Chee Leng Goh, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Elizabeth Bancroft i in. "Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer." Journal of Clinical Oncology 31, nr 6_suppl (20.02.2013): 29. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.29.
Pełny tekst źródłaJoó, József Gábor, Szabolcs Ládi, B. Zsolt Nagy i Zoltán Langmár. "Management of hereditary ovarian cancer". Orvosi Hetilap 152, nr 40 (październik 2011): 1596–608. http://dx.doi.org/10.1556/oh.2011.29218.
Pełny tekst źródłaPal, Tuya, Deborah Cragun, Xuefeng Wang, Sean J. Yoder, Tania MESA, Marilin Rosa, Ann Tezak, Anne Weidner, Susan Thomas Vadaparampil i Catherine Phelan. "Characterization of germline and tumor genomic profile in unselected young black breast cancer patients." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e13090-e13090. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13090.
Pełny tekst źródłaVidra, Radu, Tudor Eliade Ciuleanu, Adina Nemeș, Oana Pascu, Ana Maria Heroiu, Nicoleta Antone, Andreea Iulia Vidrean i in. "Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients". International Journal of Environmental Research and Public Health 19, nr 7 (4.04.2022): 4314. http://dx.doi.org/10.3390/ijerph19074314.
Pełny tekst źródłaSahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro i in. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor". International Journal of Molecular Sciences 21, nr 24 (19.12.2020): 9708. http://dx.doi.org/10.3390/ijms21249708.
Pełny tekst źródłaShao, Changxia, Michael S. Chang, Fred C. Lam, Andrew R. Marley, Huilin Tang, Yiqing Song, Chelsey Miller i in. "A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer". Journal of Oncology 2022 (20.07.2022): 1–12. http://dx.doi.org/10.1155/2022/5830475.
Pełny tekst źródłaLattimore, Vanessa, John Pearson, Arthur Morley-Bunker, kConFab Investigators, Amanda Spurdle, Bridget Robinson, Margaret Currie i Logan Walker. "Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells". International Journal of Molecular Sciences 20, nr 3 (6.02.2019): 693. http://dx.doi.org/10.3390/ijms20030693.
Pełny tekst źródłaCaleca, Laura, Mara Colombo, Thomas van Overeem Hansen, Conxi Lázaro, Siranoush Manoukian, Michael T. Parsons, Amanda B. Spurdle i Paolo Radice. "GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes". Cancers 11, nr 2 (28.01.2019): 151. http://dx.doi.org/10.3390/cancers11020151.
Pełny tekst źródłaSchwartz, Zachary Phillip, Mae Zakhour, Andrew John Li, Christine S. Walsh, Bj Rimel, Monica Alvarado, Scott E. Lentz i Ilana Cass. "Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 1547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1547.
Pełny tekst źródłaMitamura, Takashi, Masayuki Sekine, Masami Arai, Yuka Shibata, Momoko Kato, Shiro Yokoyama, Hiroko Yamashita i in. "Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome". Japanese Journal of Clinical Oncology 50, nr 12 (17.07.2020): 1380–85. http://dx.doi.org/10.1093/jjco/hyaa124.
Pełny tekst źródłaGraeser, Monika K., Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G. Froster i in. "Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers". Journal of Clinical Oncology 27, nr 35 (10.12.2009): 5887–92. http://dx.doi.org/10.1200/jco.2008.19.9430.
Pełny tekst źródłaCastro, Elena, David Olmos, Chee Leng Goh, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Elizabeth Bancroft i in. "BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 1545. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1545.
Pełny tekst źródłaLiu, Ying L., Julia Lindsay Boland, Karen Anne Cadoo, Claire Frances Friedman, Jason A. Konner, Roisin Eilish O'Cearbhaill, Carol Aghajanian i Dmitriy Zamarin. "Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 2615. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2615.
Pełny tekst źródłaTabaliuk, Y. O., L. A. Rybchenko, B. T. Klimuk i S. V. Klymenko. "Screening for mutations in BRCA1 and BRCA2 genes and related perspectives for the healthcare system". Visnik ukrains'kogo tovaristva genetikiv i selekcioneriv 18, nr 1-2 (29.01.2021): 44–57. http://dx.doi.org/10.7124/visnyk.utgis.18.1-2.1354.
Pełny tekst źródłaDufloth, Rozany Mucha, Sílvia Carvalho, Juliana Karina Heinrich, Júlia Yoriko Shinzato, César Cabello dos Santos, Luiz Carlos Zeferino i Fernando Schmitt. "Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history". Sao Paulo Medical Journal 123, nr 4 (2005): 192–97. http://dx.doi.org/10.1590/s1516-31802005000400007.
Pełny tekst źródłaAyoub, Jean-Pierre, Hans Wildiers, Michael Friedlander, Banu K. Arun, Hyo S. Han, Shannon Puhalla, Yaroslav Shparyk i in. "Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial". Therapeutic Advances in Medical Oncology 13 (styczeń 2021): 175883592110596. http://dx.doi.org/10.1177/17588359211059601.
Pełny tekst źródłaDall'era, Marc, Christopher P. Evans, Chong-Xian Pan, Mamta Parikh, Primo Lara i John McPherson. "Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?" Journal of Clinical Oncology 37, nr 7_suppl (1.03.2019): 19. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.19.
Pełny tekst źródłaOh, Mok, Ali McBride, Seongseok Yun, Sandipan Bhattacharjee, Marion Slack, Joanne M. Jeter i Ivo Abraham. "BRCA1 and BRCA2 gene mutations and colorectal cancer risk: Systematic review and meta-analysis." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 605. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.605.
Pełny tekst źródłaShweash, Muhannad, Saddam Jumaa Naseer, Maisam Khider Al-anii i Thulfiqar Fawwaz Mutar. "A MOLECULAR-BASED APPROACH TO INVESTIGATE BREAST CANCER 1 AND BREAST CANCER 2 STATUS IN OVARIAN CANCER AMONG IRAQI WOMEN". Asian Journal of Pharmaceutical and Clinical Research 11, nr 7 (7.07.2018): 199. http://dx.doi.org/10.22159/ajpcr.2018.v11i7.25217.
Pełny tekst źródłaTrombetta, Mark, Katherine Kotinsley i Thomas B. Julian. "Breast conservation surgery and radiation for a patient with synchronous primary breast cancers and BRCA1/BRCA2 positivity: is mastectomy required?" Journal of Radiotherapy in Practice 11, nr 1 (18.03.2011): 62–65. http://dx.doi.org/10.1017/s1460396911000021.
Pełny tekst źródła